Insight Molecular Diagnostics (IMDX) Shares Outstanding (Diluted Average) (2022 - 2026)

Insight Molecular Diagnostics has disclosed Shares Outstanding (Diluted Average) across 5 years of filings, most recently posting $34.5 million for Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $34.5 million, up 34.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $34.5 million (up 34.35% YoY), and the FY2025 annual result was $30.5 million, up 133.16% from the prior year.
• Shares Outstanding (Diluted Average) came in at $34.5 million for Q1 2026 at Insight Molecular Diagnostics, up from $30.5 million in the prior quarter.
• In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $92.2 million in Q1 2022 to a low of $5652.0 in Q2 2022.
• The 5-year median for Shares Outstanding (Diluted Average) is $12.9 million (2024), against an average of $19.3 million.
• Peak annual rise in Shares Outstanding (Diluted Average) reached 143035.17% in 2023, while the deepest fall reached 93.54% in 2023.
• Insight Molecular Diagnostics' Shares Outstanding (Diluted Average) stood at $5.5 million in 2022, then surged by 38.1% to $7.7 million in 2023, then soared by 70.84% to $13.1 million in 2024, then soared by 133.16% to $30.5 million in 2025, then climbed by 13.27% to $34.5 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $34.5 million (Q1 2026), $30.5 million (Q4 2025), and $29.9 million (Q3 2025), per Business Quant data.